Trials / Completed
CompletedNCT04079530
A Clinical Pharmacology Study of K-877 Controlled Release Tablet
A Multicenter, Randomized, Active-controlled, Single-blind, 2-Period, 12-Sequence Crossover Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Pemafibrate in Patients With Dyslipidemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Kowa Company, Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | K-877 IR 0.2 mg/day | K-877 IR 0.1 mg tablet |
| DRUG | K-877 CR 0.4 mg/day | K-877 CR 0.4 mg tablet |
| DRUG | K-877 CR 0.8 mg/day | Two K-877 CR 0.4 mg tablet |
Timeline
- Start date
- 2019-09-13
- Primary completion
- 2019-12-24
- Completion
- 2019-12-24
- First posted
- 2019-09-06
- Last updated
- 2025-10-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04079530. Inclusion in this directory is not an endorsement.